|
Friday 22nd June 2012 |
Text too small? |
Fruit grower and coolstore and packhouse operator Seeka Kiwifruit Industries has reassured the market that no antibiotic tainted fruit entered the market.
In a trial update release on the pan-industry fight against the vine bacterial disease Pseudomona Syringae pv actinidiae, Seeka said it has been involved in approved trials testing the use of antibiotics as a defence.
The trials used streptomycin and oxytectracyclin and “were carried out under strict control processes following careful planning,” said Seeka chief executive Michael Franks, following recent media reports about antibiotic use in the kiwifruit industry.
There was never any intention to harvest fruit for consumption, all fruit was destroyed, he said.
One trial that commenced without the orchard specific approval by the Agricultural Compounds and Veterinary Medicines had been brought to ACVM’s attention by Seeka, Franks said.
Findings from these Seeka trials have been presented to the industry at its recent technical forums in the scientific advance for a cure for Psa-V.
Franks said regular monitoring across the industry is key to ensuring no antibiotic residue on any fruit.
Seeka's shares were unchanged at $1.76 today, and have surged 79 percent this year.
New Zealand's kiwifruit industry came under pressure after the Psa-V bacteria was discovered in 2010, infecting more than 40 percent of the nation's kiwifruit hectares.
BusinessDesk.co.nz
No comments yet
TWL - Share Purchase Plan Results
GMT revaluation, unit buyback and proposed structure update
Devon Funds Morning Note - 17 February 2026
CEN - Contact successfully completes NZ$450m Placement
February 17th Morning Report
PFI - Divestments
CEN offers to purchase remaining 25% of King Country Energy
February 16th Morning Report
SkyCity Appoints Chief Financial Officer
February 13th Morning Report